Search
Displaying 551–560 of 1143 results
-
Seeing Research Advances Firsthand
Beacon StoriesMark does not let his retinitis pigmentosa diagnosis keep him from doing what he loves most, including spending quality time with his family. And in 2019, Mark began participating in a clinical trial, which he describes as life-changing.
-
Opus Genetics Announces Two Key Leadership Appointments
In the PressDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Learning to Fall After Vision Loss
Beacon StoriesWhen Justin’s vision loss progressed quickly due to retinitis pigmentosa at 25 years old, he thought skateboarding wouldn’t be possible anymore. Ten years later, with the help of his white cane and audio devices, Justin is now working to enhance accessibility in skateboarding for the blind and visually impaired community.
-
Foundation Fighting Blindness Appoints Richele Donat, SPHR, as Chief Human Resources Officer
Foundation NewsMs. Donat brings over twenty years of successful human resource leadership experience to the Foundation executive team
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Covid Revealed What Science Can Do When Funding is Found
In the Press‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
RD Fund Appoints Tony Adamis, MD to Board of Directors
Foundation NewsThe RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Research News
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
Research NewsFirst two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
